Outcome Statement of the Paediatric Medicines Advisory Group (PMAG) meeting 31 October 2012

Outcome Statement of the National Medicines Policy Committee - October 2012

Page last updated: 12 December 2012

PDF printable version of the Outcome Statement of the Paediatric Medicines Advisory Group (PMAG) meeting 31 October 2012 (PDF 147 KB)

Medicine needs in the paediatric health setting

PMAG has identified a priority list of medicines requiring access for paediatric use in Australia, with some alterations made at this meeting. The medicines currently under consideration by PMAG are at Attachment A.

Members noted that, as a result of PMAG’s efforts, the listing for atenolol on the Pharmaceutical Benefits Scheme will be effective on 1 December 2012 and the listing for etanercept injection has been amended on 1 August 2012.

Liaison with stakeholders

Members noted that PMAG had liaised with a number of pharmaceutical companies and expert paediatric groups since the last meeting to further discuss a number of medicines on PMAG’s priority list, and to seek advice on specific issues in paediatric medicine.

Liaison with other agencies

Members noted that liaison with the Editorial Executive Committee of the Australian Prescriber would continue in relation to an article on the work that is being done to improve the availability of medicines for paediatric use in Australia.

PMAG is also involved in current antibiotic resistance surveillance activity, which is being led by the Australian Commission on Safety and Quality in Healthcare.

National and International developments

Members noted the ongoing national and international developments to improve access to medicines suitable for paediatric use. In terms of national developments, members noted the progress on the national paediatric medicines dosing resource.

Meeting Outcomes

Outcome statements are provided after each meeting, so that members can distribute them widely to their networks. For further information on the Advisory Group, please visit the Paediatric Medicines Advisory Group webpage:
or contact the Advisory Group Secretariat:

Phone: (02) 6289 8023
Email: pmag@health.gov.au


Medicines currently under PMAG consideration - as at 31 October 2012

Clinical need as agreed by the PMAG
Clindamycin suspensionCommunity acquired MRSA (in skin and soft tissue infection) and osteomyelitis
Calciferol/cholecalciferolVitamin D deficiency
Clobazam tabletsResistant epilepsy
Triamcinolone hexacetonideSteroid joint injections for juvenile idiopathic arthritis
Mycophenolate sodiumNephrotic syndrome
Diazepam mixtureChronic spasticity
LeuprorelinPrecocious puberty
AdalimumabUveitis related to juvenile idiopathic arthritis, enthesitis and crohn disease
AnakinraSystemic juvenile idiopathic arthritis
LeflunomideJuvenile idiopathic arthritis
InfliximabAnkylosing spondylitis
AbataceptPolyarticular juvenile idiopathic arthritis
BosentanPulmonary hypertension
Glycopyrrolate oral solutionDrooling
MelatoninSleep disorders (particularly those with neurological impairment/cortical blindness)
NatalizumabRefractory multiple sclerosis
KindergenMedicinal food for older children
6-Mercaptopurine and Thioguanine suspensionAcute leukaemia
Tacrolimus suspensionOrgan transplant